I. POLICY/CRITERIA

Special Note: This policy applies to adults age 18 and older only.

A. Testing and Diagnosis

All studies (with the exception of home sleep studies) require prior authorization. The studies must be done by a certified sleep lab facility and be read by a certified sleep specialist. There are no limitations on referrals to in-network sleep specialists. Prior authorization is not required for ages younger than 18 years.

1. Home/portable sleep apnea studies (HSAT) are considered medically necessary for individuals clinically suspected of having obstructive sleep apnea (OSA), and who do not have any of the following:
   a. HF (heart failure) NYHA Class III and IV, EF (Ejection Fraction) < 50%, or Class II Diastolic Dysfunction
   b. Cardiac arrhythmia (e.g. atrial fibrillation, SVT, ventricular arrhythmia)
   c. History of myocardial infarction or coronary artery disease in last 12 months
   d. Moderate to severe pulmonary disease (e.g., chronic respiratory disease / symptomatic lung disease / pulmonary hypertension)
   e. Neuromuscular disease
   f. Stroke or TIA within the last 12 months
   g. Cognitive impairment, behavioral health issues or other social circumstances that compromise administration of a home sleep test (HST)
   h. Seizure disorder

Prior authorization is not required for home sleep apnea studies and may be ordered by any licensed physician or advanced practice provider.
In addition to meeting criteria in #1 above, evaluation using HSAT is covered if clinical interpretation is performed by a board certified sleep specialist and HSAT is provided by Medicare certified participating provider with a device described below.

Unattended (home) sleep studies using any of the following diagnostic techniques is medically necessary for members with symptoms suggestive of OSA when the home sleep study is used as part of a comprehensive sleep evaluation:

a. Sleep monitoring using a Type II device, or
b. Sleep monitoring using a Type III device, or
c. Sleep monitoring using a Type IV(A) device, measuring airflow and at least 2 other channels and providing measurement of apnea-hypopnea index (AHI)

Note: Sleep studies using devices that do not provide a measurement of apnea-hypopnea index (AHI) and oxygen saturation are considered not medically necessary because they do not provide sufficient information to prescribe treatment. Examples include the Biancamed SleepMinder, SNAP testing with fewer than three channels, and the SleepImage Sleep Quality Screener. Note that the ApneaLink does not meet criteria as a covered type IV device because it does not measure airflow; however, the ApneaLink Plus records 5 channels, including airflow, and meets criteria for a covered sleep study device.

2. Attended sleep studies or polysomnogram (PSG) may be considered medically necessary for individuals with suspected OSA as determined by clinical symptoms and one of the following:
   a. Any of the clinical symptoms outlined in (a - h) in 1 above; or
   b. Two failed, incomplete, or inadequate HSATs with significant indicators of OSA; or
   c. One technically complete or adequate negative HSAT with high suspicion of OSA (presumptive false negative); or
   d. On patients who demonstrate Cheyne-Stokes Respiration (CSR) on HSAT; or
   e. Individual currently being treated with a dental appliance with moderate to severe OSA (AHI>15) at baseline.

3. Emergency criteria to allow for Split Night Studies:
   In the event that moderate to severe OSA was not anticipated prior to ordering PSG, and to ensure safety during PSG, conversion to a Split Night Study is considered medically necessary if all criteria below are met:
   a. OSA is diagnosed by AHI as defined below on PSG.
   b. Oxygen desaturation as defined by SaO₂ <75% is present during PSG.
c. Member has been counseled in sleep related respiratory events (apnea, hypopnea, sleep arousal, AHI) and the mechanics of PAP therapy for the treatment of OSA have been reviewed.
d. Emergency criteria to allow for a split-night study have been reviewed with the patient in advance of PSG.

Split Night study is not considered medically necessary if documentation of a specific treatment plan exists that does not include CPAP therapy. Examples include a planned referral to a dentist for a mandibular advancement appliance, plans for upper airway surgery, or a statement that the patient does not want any treatment until the results of the test are reviewed by the sleep specialist.

4. Attended sleep studies or polysomnogram (PSG) may be considered medically necessary when a certified sleep specialist suspects one of the following sleep disorders prior to PSG:
   - narcolepsy
   - idiopathic hypersomnia
   - clinically significant parasomnia disorders
   - periodic limb movement disorder
   - central sleep apnea
   - obesity hypoventilation syndrome with BMI >45, and hypoventilation with documented hypoxia

5. Repeat facility-based PSG are a covered benefit when the above criteria in #2 for a PSG are met and for evaluation of one of the following:
   a. the discontinuation of PAP or oral appliance after surgery (oral surgery, UPPP); or
   b. resolution of OSA after surgical treatment for OSA (oral surgery, UPPP); or
   c. resolution of OSA following significant weight loss >10% such as that associated with bariatric surgery.
   d. resolution of symptoms with oral appliance.

6. CPAP Titration Studies may be covered if any of the following criteria are present:
   - Moderate to severe pulmonary disease (e.g. chronic respiratory disease / symptomatic lung disease / pulmonary hypertension)
   - Congestive heart failure or recent MI within the last 6 months
   - Cognitive impairment that compromises administration of a home apnea sleep test (HSAT)
   - OSA with severe desaturation (oxygen desaturations either a) >5 continuous minutes with SaO2 <87% or b) 5 total minutes with SaO2 <80%)
• Other comorbid sleep disorder as listed in 4 above, in addition to OSA
• Failure of home APAP titration

7. PAP-NAP (95807-52, involving mask fit, patient desensitization and leak control during a daytime nap while monitoring airflow, respiratory effort, EKG and oximetry) in a patient diagnosed with sleep apnea using in center or HSAT testing and meeting criteria for PAP prescription is covered in the following situations:
   a. In patients prescribed PAP who have less than 70% compliance in the first 30 days of use; or
   b. In patients unable to tolerate home titration (i.e. moderate to severe mental illness, cognitive impairment, claustrophobia, insomnia < 6 hours of sleep).

8. The Multiple Sleep Latency Test (MSLT) is covered according to InterQual® criteria.

B. Treatment of OSA

1. The following treatment modalities are covered for OSA when InterQual® are met:
   a. Auto-titrating positive airway pressure (APAP), or
   b. Continuous Positive Airway Pressure (CPAP) if medically indicated.
      • BiPAP, DPAP, and VPAP are covered as DME.
      • Humidifiers and heaters for positive airway pressure devices are covered.
      • A nasal/face mask or an oral pressure appliance (Oral Positive Airway Pressure - OPAP) are covered as durable medical equipment.
   c. Oral Appliance. Covered under Prosthetics and Orthotics benefit level, applicable copays apply.

2. *Uvulopalatopharyngoplasty (UPPP), uvulecory, or any other procedures to correct obstructive sleep apnea, are covered benefits if both of the following apply:
   a. Obstructive Sleep Apnea (OSA)
   b. Respiratory Event Index (REI) or Apnea/Hypopnea Index (AHI) is 15 or greater on polysomnography, or two or more of the following are met:
      • AHI>5 and <15
      • >20 episodes of oxygen desaturation < 85% or any one episode of oxygen desaturation < 70%
• Type II second degree heart block or pause > 3 seconds or ventricular tachycardia at a rate > 140/minute lasting > 15 complexes
• Excessive daytime sleepiness documented by either Epworth Sleepiness Scale > 10 or Multiple Sleep Latency Test (MSLT) < 8

*A three (3) month trial of CPAP must be completed prior to UPPP. UPPP is a surgical procedure in which the oropharynx is enlarged by excision of the uvula and tissue of the soft palate. A tonsillectomy may also be done with the UPPP; payment for the tonsillectomy will be considered incidental to the more comprehensive UPPP procedure. UPPP, when medically necessary, is a covered benefit.

C. The following are **not covered** benefits (this list is not all-inclusive):

a. **Laser - Assisted Uvulopalatoplasty (LAUP).** LAUP has not been proven to be an appropriate or effective treatment of OSA or UARS. (The treatment of snoring by LAUP is not a covered benefit.)

b. **Radiofrequency Ablation** of the tongue base, uvula or soft palate (Somnoplasty) or of the nasal passages and soft palate (Coblation) is considered experimental and investigational as a treatment for obstructive sleep apnea because there is inadequate scientific evidence to validate the effectiveness of these procedures for this indication.

c. **Pillar Procedure.** There is a lack of evidence of short-term or long-term effectiveness of palatal restoration, or Pillar Procedure when performed for either obstructive sleep apnea or snoring. Palatal implant is covered for Medicare patients who meet certain Medicare criteria.

d. **Tongue-base suspension (i.e., Repose).** The suspension of the anterior tongue by fixation of the soft tissue to the mandible using a bone screw is considered to be experimental and investigational.

e. **Partial Glossectomy** surgical removal of a portion of the tongue or oral cavity in an effort to widen the hypopharynx is considered to be experimental and investigational.

f. Hypoglossal neurostimulation for obstructive sleep apnea (e.g. Inspire II, aura6000 Targeted Hypoglossal Neurostimulation (THN) Sleep Therapy System) is considered experimental and investigational

g. **Maintenance of Wakefulness Test (MWT)** objectively measures the ability of an individual to remain awake for a defined period of time. Although the MWT has been used to evaluate the risk for driving, work, or home-related accidents, its validity for this purpose has not been proven and is not a covered benefit.
Definitions:

The Apnea/Hypopnea Index (AHI) is determined by attended polysomnography, equal to the total number or apneas and hypopneas x 60 divided by the total sleep time in minutes. Apnea is scored if airflow is reduced by >90% for at least 10 seconds. Hypopneas are scored if there is a drop by >30% of pre-event baseline airflow lasting at least 10 seconds, resulting in an EEG arousal or >3% oxyhemoglobin desaturation.

The Respiratory Event Index (RDI) is equal to the average number of episodes of apnea and hypopnea events per hour of recording and must be based on a minimum of 2 hours of time recorded by unattended polysomnography. Apnea is defined as a cessation of airflow for at least 10 seconds. Hypopnea is defined as an abnormal respiratory event lasting at least 10 seconds with at least a 30% reduction in airflow as compared to baseline, resulting in at least a 3% oxyhemoglobin desaturation.

If the AHI or REI is calculated based on less than 2 hours of sleep or recording time, the total number of recorded events used to calculated the AHI or RDI (respectively) must be at least the number of events that would have been required in a 2 hour period (i.e., must reach ≥30 events without symptoms or ≥10 events with symptoms).

II. MEDICAL NECESSITY REVIEW

✔️ Required - for in-center sleep testing and capped rental positive pressure appliances (see below)
✔️ Not Required – for home sleep testing, surgery; PAP supplies and oral appliances - unless DME/P&O dollar threshold exceeded (greater than $1,000; $500 for Priority Health Medicaid).
☐ Not Applicable

III. APPLICATION TO PRODUCTS

Coverage is subject to member’s specific benefits. Group specific policy will supersede this policy when applicable.

❖ HMO/EPO: This policy applies to insured HMO/EPO plans.
❖ POS: This policy applies to insured POS plans.
❖ PPO: This policy applies to insured PPO plans. Consult individual plan documents as state mandated benefits may apply. If there is a conflict between this policy and a plan document, the provisions of the plan document will govern.
❖ ASO: For self-funded plans, consult individual plan documents. If there is a conflict between this policy and a self-funded plan document, the provisions of the plan document will govern.
INDIVIDUAL: For individual policies, consult the individual insurance policy. If there is a conflict between this medical policy and the individual insurance policy document, the provisions of the individual insurance policy will govern.

MEDICARE: Coverage is determined by the Centers for Medicare and Medicaid Services (CMS); if a coverage determination has not been adopted by CMS, this policy applies.

MEDICAID/HEALTHY MICHIGAN PLAN: For Medicaid/Healthy Michigan Plan members, this policy will apply. Coverage is based on medical necessity criteria being met and the appropriate code(s) from the coding section of this policy being included on the Michigan Medicaid Fee Schedule located at: http://www.michigan.gov/mdch/0,1607,7-132-2945-42542-42543-42546-42551-159813--,00.html. If there is a discrepancy between this policy and the Michigan Medicaid Provider Manual located at: http://www.michigan.gov/mdch/0,1607,7-132-2945-5100-87572--,00.html, the Michigan Medicaid Provider Manual will govern.

For Medical Supplies/DME/Prosthetics and Orthotics, please refer to the Michigan Medicaid Fee Schedule to verify coverage.

IV. DESCRIPTION

Obstructive Sleep Apnea (OSA) is characterized by the collapse and obstruction of the upper airway during sleep, leading to sleep fragmentation. In this syndrome, respiratory efforts persist but are ineffective due to obstruction that may occur anywhere in the upper airway. The most common complaints associated with OSA are snoring and excessive daytime sleepiness. Snoring, although it may be a social problem, is not a medical condition. The treatment of snoring alone is not a covered benefit. There must be objective evidence of sleep apnea on polysomnography or Multiple Sleep Latency Test for coverage of treatment. Testing for OSA is a covered benefit.

Standard Classifications of OSAS according to Apnea/Hypopnea Index (AHI)\(^{15}\)

- Mild: greater than 5 and less than 15
- Moderate: 15 to 30
- Severe: greater than 30

The diagnosis of sleep apnea may require confirmation by sleep laboratory studies. Patients’ symptoms and the frequency of respiratory events on laboratory testing are important factors in determining the severity of disease. In patients with mild sleep apnea, conservative treatment measures include getting sufficient sleep, abstaining from the use of alcohol, tobacco, and sedatives, losing weight, and avoiding the supine position during sleep. Many patients with documented sleep apnea require more than conservative therapy. Continuous positive airway pressure (CPAP) is the most consistently effective treatment for clinically significant obstructive sleep apnea.

Palatal surgical procedures tend to alleviate snoring but are not consistently effective in treating sleep apnea. Many patients with sleep apnea have airway obstruction beyond the palatal area that is not treated by soft tissue procedures.
V. CODING INFORMATION

ICD-10 Codes that may apply:

- G47.10 – G47.19 Hypersomnia
- G47.30 Sleep apnea, unspecified
- G47.31 Primary central sleep apnea
- G47.33 Obstructive sleep apnea (adult) (pediatric)
- G47.34 Idiopathic sleep related nonobstructive alveolar hypoventilation
- G47.35 Congenital central alveolar hypoventilation syndrome
- G47.36 Sleep related hypoventilation in conditions classified elsewhere
- G47.37 Central sleep apnea in conditions classified elsewhere
- G47.39 Other sleep apnea
- G47.411 – G47.429 Narcolepsy
- G47.50 – G47.59 Parasomnia
- G47.8 Other sleep disorders
- G47.9 Sleep disorder, unspecified
- R06.00 Dyspnea, unspecified
- R06.09 Other forms of dyspnea
- R06.3 Periodic breathing
- R06.83 Snoring
- R06.89 Other abnormalities of breathing

Covered CPT/HCPCS Codes when policy criteria met:

- Limitations apply for Priority Health Medicare – see LCD

Home Sleep Studies
- 95800 Sleep study, unattended, simultaneous recording; heart rate, oxygen saturation, respiratory analysis (eg, by airflow or peripheral arterial tone), and sleep time
- 95801 Sleep study, unattended, simultaneous recording; minimum of heart rate, oxygen saturation, and respiratory analysis (eg, by airflow or peripheral arterial tone)
- 95806 Sleep study, simultaneous recording of ventilation, respiratory effort, ECG or heart rate, and oxygen saturation, unattended by a technologist (Not covered for Priority Medicaid)
- G0398 Home sleep study test (HST) with type II portable monitor, unattended; minimum of 7 channels: EEG,EOG,EMG,ECG/heart rate, airflow, respiratory effort and oxygen saturation (Not covered for Priority Medicaid)
- G0399 Home sleep test (HST) with type III portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ECG/heart rate and 1oxyg en saturation (Not covered for Priority Medicaid)
- G0400 Home sleep test (HST) with type IV portable monitor, unattended; minimum of 3 channels (Not covered for Priority Medicaid)

In Center Sleep Studies – Prior Authorization (PA) required
(PA not required for members 0 – 18 years)
- 95807 Sleep study, simultaneous recording of ventilation, respiratory effort, ECG or heart rate, and oxygen saturation, attended by a technologist

Append modifier 52 for PAP NAP billing
95808  Polysomnography; any age, sleep staging with 1-3 additional parameters of sleep, attended by a technologist
95810  Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, attended by a technologist
95811  Polysomnography; age 6 years or older, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bi-level ventilation, attended by a technologist
95805  Multiple sleep latency or maintenance of wakefulness testing, recording, analysis and interpretation of physiological measurements of sleep during multiple trials to assess sleepiness

No prior authorization required:
94660  Continuous positive airway pressure ventilation (CPAP), initiation and management
Consultation with a registered respiratory therapist or registered polysomnographic technologist at the time of initial treatment and or during or immediately after the initial 90 days of treatment with any of the PAP therapy devices to ensure appropriate use and fit of equipment and associated devices will be covered.

95782  Polysomnography; younger than 6 years, sleep staging with 4 or more additional parameters of sleep, attended by a technologist
95783  Polysomnography; younger than 6 years, sleep staging with 4 or more additional parameters of sleep, with initiation of continuous positive airway pressure therapy or bi-level ventilation, attended by a technologist

Check plan benefit limitations for surgical services
42140  Uvulectomy, excision of uvula
42145  Palatopharyngoplasty (eg, uvulopalatopharyngoplasty, uvulopharyngoplasty)

ICD-10 Code that is payable for the following codes:
G47.33  Obstructive sleep apnea (adult) (pediatric)

CPT/HCPCS Codes:
E0485  Oral device/appliance used to reduce upper airway collapsibility, adjustable or non-adjustable, prefabricated, includes fitting and adjustment (Not covered for Priority Medicaid or Medicare)
E0486  Oral device/appliance used to reduce upper airway collapsibility, adjustable or non-adjustable, custom fabricated, includes fitting and adjustment (Not covered for Priority Medicaid)

Authorization required for all plans
- Capped rental; DME benefit
- Prior Authorization waived one time for the 1st three months rental. If treatment is not continued after 3 months but is resumed at a later time, prior authorization will be required from the start of treatment for the first 3 months and to continue for the following 7 months (10 months for Medicare) of the capped rental period.
Requests for prior authorization must include evidence of compliance defined as use of PAP ≥4 hours per night for a minimum of 21 nights (70% of nights) during a consecutive thirty (30) day period anytime during the first three (3) months of usage.

E0470 Respiratory assist device, bi-level pressure capability, without backup rate feature, used with noninvasive interface, e.g., nasal or facial mask (intermittent assist device with continuous positive airway pressure device)

E0471 Respiratory assist device, bi-level pressure capability, with backup rate feature, used with noninvasive interface, e.g., nasal or facial mask (intermittent assist device with continuous positive airway pressure device)

E0472 Respiratory assist device, bi-level pressure capability, with backup rate feature, used with noninvasive interface, e.g., tracheostomy tube (intermittent assist device with continuous positive airway pressure device) (Not covered for Priority Medicaid)

E0601 Continuous airway pressure (CPAP) device

Non-covered CPT/HCPCS Codes:
95803 Actigraphy testing, recording, analysis, interpretation, and report (minimum of 72 hours to 14 consecutive days of recording)

41120 Glossectomy; less than 1/2 tongue (not covered for sleep related conditions)

41130 Glossectomy; hemiglossectomy (not covered for sleep related conditions)

41512 Tongue base suspension, permanent suture technique

41530 Submucosal ablation of the tongue base, radiofrequency, 1 or more sites, per session

42160 Destruction of lesion, palate or uvula (thermal, cryo or chemical) (covered for non-sleep related indications with prior auth)

42299 Unlisted procedure, palate, uvula (Not covered if billed for somnoplasty or any other not covered procedure. Explanatory notes must accompany claim)

C9727 Insertion of implants into the soft palate; minimum of three implants

S2080 Laser-assisted uvulopalatoplasty (LAUP)

E0190 Positioning cushion/pillow/wedge, any shape or size, includes all components and accessories

E1399 Durable medical equipment, miscellaneous (Explanatory notes must accompany claim)

Not covered for devices such as Provent® and/or other devices not recognized as covered in this policy.

0424T Insertion or replacement of neurostimulator system for treatment of central sleep apnea; complete system (transvenous placement of right or left stimulation lead, sensing lead, implantable pulse generator)

0425T Insertion or replacement of neurostimulator system for treatment of central sleep apnea; sensing lead only

0426T Insertion or replacement of neurostimulator system for treatment of central sleep apnea; stimulation lead only
0427T Insertion or replacement of neurostimulator system for treatment of central sleep apnea; pulse generator only
0428T Removal of neurostimulator system for treatment of central sleep apnea; pulse generator only
0429T Removal of neurostimulator system for treatment of central sleep apnea; sensing lead only
0430T Removal of neurostimulator system for treatment of central sleep apnea; stimulation lead only
0431T Removal and replacement of neurostimulator system for treatment of central sleep apnea, pulse generator only
0432T Repositioning of neurostimulator system for treatment of central sleep apnea; stimulation lead only
0433T Repositioning of neurostimulator system for treatment of central sleep apnea; sensing lead only
0434T Interrogation device evaluation implanted neurostimulator pulse generator system for central sleep apnea
0435T Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; single session
0436T Programming device evaluation of implanted neurostimulator pulse generator system for central sleep apnea; during sleep study
0466T Insertion of chest wall respiratory sensor electrode or electrode array, including connection to pulse generator (List separately in addition to code for primary procedure)
0467T Revision or replacement of chest wall respiratory sensor electrode or electrode array, including connection to existing pulse generator
0468T Removal of chest wall respiratory sensor electrode or electrode array

VI. REFERENCES


Centers for Medicare and Medicaid (CMS) Coverage Database, National Coverage Determination (NCD), NCD for Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea (OSA) (240.4), Pub. 100-3, Effective date: 04/04/2005.


Portable Devices for home testing for obstructive sleep apnea – California Technology Assessment Forum June 15, 2005

Wisconsin Physicians Service (WPS), National Coverage Provision (NCP), Surgical Treatment of Obstructive Sleep Apnea, ENT-012, Michigan effective date: 07/01/2002, Revision effective date: 10/01/2006

Wisconsin Physicians Service (WPS), National Coverage Provision (NCP), Sleep-Disorder Clinics and Diagnostic Tests, PULM-0003, Michigan effective date: 10/15/1997, Revision date: 10/01/2005.

Hayes Technology Brief: Repose® Tongue and Hyoid Suspension (THS) system (Medtronic Xomed Inc.) January 31, 2010

Hayes Technology Brief: Pillar® Palatal Implant System (Medtronic Xomed Inc.) January 28, 2010

Up-to-Date: Management of obstructive sleep apnea in adults Last literature review version 18.1: January 2010 | This topic last updated: December 7, 2009

Hayes, Inc. aura6000 Targeted Hypoglossal Neurostimulation (THN) Sleep Therapy System January 2015
